Investment Rating - The report does not explicitly state an investment rating for the dry eye disease treatment industry Core Insights - The dry eye disease market in China is experiencing significant growth, with the number of patients increasing from 300 million in 2020 to 360 million in 2024, representing a compound annual growth rate (CAGR) of approximately 5% [7] - The treatment rate for dry eye disease remains low at 10%-12%, indicating substantial market potential [3] - The market is evolving from traditional artificial tears to innovative therapies, including preservative-free formulations and new drug delivery systems, driven by advancements in formulation technology [3] - Local pharmaceutical companies are making breakthroughs in anti-inflammatory mechanisms and targeted therapies, leading to a new competitive landscape focused on innovative drugs and precision treatment [3] Market Background - The dry eye disease market has evolved through three stages: the nascent stage (1995-2005), the initiation stage (2006-2015), and the rapid development stage (2016-present) [5][6] - The current market is characterized by a shift from foreign dominance to a competitive landscape involving both domestic and foreign companies [12] Market Status - The market size is projected to reach 139 billion yuan in 2024, with expectations to grow to 193 billion yuan by 2030, reflecting a CAGR of about 9% [7] - The supply chain includes high-activity raw materials and a diverse range of products, with foreign companies currently holding a significant market share in artificial tears [8] - Demand for treatments is increasing, particularly among moderate to severe dry eye patients who require combination therapies [9] Market Competition - The competitive landscape is marked by a clear tiered structure, with leading companies like Santen Pharmaceutical and domestic firms like Xingqi Eye Medicine dominating the first tier [12] - The report identifies ten key brands in the market, highlighting their strengths and market positions [13] - Domestic companies are increasingly closing the gap with foreign firms through innovation and strategic partnerships [12] Development Trends - The market is expected to maintain a growth rate of around 9% from 2025 to 2030, driven by advancements in diagnostic technologies and innovative therapies [27] - Drug innovation is diversifying, with traditional drugs being upgraded and new treatment modalities emerging [28] - Local companies are expanding globally, with firms like Heng Rui Medicine and Xingqi Eye Medicine leading the charge in international markets [29]

Investment Rating - The report indicates a positive investment outlook for the dry eye disease treatment drug industry, with a projected compound annual growth rate (CAGR) of 10% from 2025 to 2030, and the market size expected to exceed 9.6 billion yuan by 2030 [4][31]. Core Insights - The dry eye disease treatment market in China is characterized by a dual-track competition between foreign and domestic companies, with local firms like Xingqi Eye Medicine and Hengrui Medicine gradually breaking the monopoly of foreign enterprises through independent research and development and collaborative efforts [4][10]. - The number of dry eye disease patients in China has surpassed 360 million, with an annual growth rate of 10%, indicating a continuous expansion of diagnosis and treatment demand [4][11]. - The market is shifting from reliance on traditional treatments like artificial tears to innovative therapies, including immunosuppressants and new drug delivery systems, marking a transition to a more precise and individualized treatment approach [4][17][34]. Summary by Sections Industry Definition - Dry eye disease (DED) is caused by insufficient tear production or instability of the tear film, leading to various ocular discomforts. Treatment is individualized and can include drug therapy, physical therapy, and surgical options [5]. Drug Classification - Dry eye treatment drugs can be categorized based on their mechanisms of action, including lubricating and repairing agents, anti-inflammatory drugs, and antibacterial agents [6][7][8]. Industry Characteristics - The increase in screen time among residents has led to a rise in dry eye disease cases, creating significant market potential. The market is currently dominated by artificial tears and cyclosporine eye drops [10][12]. Market Size and Growth - The market size for dry eye treatment drugs is projected to grow from 12.755 billion yuan in 2025 to 19.306 billion yuan by 2030, with a CAGR of 8.64% [31][34]. Competitive Landscape - The high-end market for dry eye treatment drugs is primarily dominated by foreign brands, but domestic companies are making significant strides through innovation and competitive pricing [41][42][43]. Policy Analysis - Recent policies aim to enhance eye health services and promote awareness of dry eye disease, which is expected to further stimulate market growth [39][40]. Industry Chain Analysis - The industry chain includes upstream raw material suppliers, midstream drug manufacturers, and downstream sales channels, with a focus on innovation and quality improvement to enhance competitiveness [18][19][20].